Copy Link
London, UK – 13 April 2026, Vitaccess, a leader in generating science-driven real-world evidence, today announced the appointment of Matt Reaney as Chief Scientific Officer (CSO), expanding the company’s executive team.
Matt brings over two decades of experience in patient-centered science and clinical outcome assessment (COA). He most recently led Global Science & Analytics for Patient Centered Solutions at IQVIA, where he shaped scientific strategy for interpreting patient experience data across clinical research. Prior to this, Matt served as Head of Clinical Outcomes Generation at Sanofi, and his earlier leadership roles at Eli Lilly, ERT, and Oxford Outcomes built deep expertise in real-world evidence across various therapeutic areas.
Alongside his industry experience, Matt serves on the Scientific Advisory Council for Breakthrough T1D UK, a leading diabetes research and advocacy charity. He is an Expert in Residence at the University of Oxford, and a tenured guest lecturer at Royal Holloway University of London . He brings a wealth of experience as a Chartered and Practitioner Health Psychologist and Chartered Scientist, and plays a key role in advancing patient-centered science through his numerous fellowship roles (Royal Society of Medicine, Royal Society of Public Health, British Psychological Society) and as co-chair of the Drug Information Association Study Endpoints Community.
“Matt’s extensive knowledge and experience in patient-centred research comes at an important time for Vitaccess and the real-world evidence space,” said Mark Larkin, PhD, CEO and Founder of Vitaccess. “As regulatory bodies, payers and other stakeholders increasingly adopt patient-centered approaches in decision making, Matt’s expertise will be a major asset to the company. His appointment further strengthens our scientific leadership, as we continue to translate patient insights into meaningful impact for people worldwide.”
Matt Reaney, PhD, Chief Scientific Officer at Vitaccess, commented: “I’m hugely excited to join Vitaccess. Mark and the team have built a genuinely differentiated offering that benefits patients, builds trust, encourages engagement and results in better insights into how patients experience disease and treatment in their daily lives. I look forward to working alongside the team as we transform complex real-world data into insights that truly make a difference.”
About Vitaccess
Vitaccess is a UK-based leader in real-world evidence generation, closing the insight gap for biopharma companies worldwide by putting patient voices at the center of research that matters. Through scientifically rigorous, expert-led patient research, we deliver the full spectrum of evidence generation, from longitudinal registries through to qualitative concept elicitation. Vitaccess can integrate patient-reported outcomes, clinical data, qualitative research, and preference studies, providing nuanced real-world evidence that supports global payer and regulatory decision-making, across a range of therapeutic areas, including rare disease, neurology, cardiovascular and metabolic, oncology, respiratory, and haematology.
To learn more, visit our website: https://vitaccess.com/
Media contacts
Vitaccess
ICR Healthcare
Tracy Cheung, Chris Welsh,
